{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:48:56Z","timestamp":1790686136661,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001707","name":"Union for International Cancer Control","doi-asserted-by":"publisher","award":["TF-20\\u2013716796"],"award-info":[{"award-number":["TF-20\\u2013716796"]}],"id":[{"id":"10.13039\/501100001707","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ctrv.2025.103069","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:11:50Z","timestamp":1765901510000},"page":"103069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4\/6 inhibitors in hormone receptor-positive HER2-negative breast cancer \u2013 A systematic review and meta-analysis"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4805-2101","authenticated-orcid":false,"given":"Yee-Yin","family":"Hoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wei","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharminii","family":"Jaya-Prakason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogda","family":"Koczwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yek-Ching","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Dechartres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmala","family":"Bhoo-Pathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103069_bib326","unstructured":"IARC. Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020 Press Release. World Health Organization 2020; Available from: https:\/\/www.iarc.who.int\/news-events\/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020\/."},{"issue":"2","key":"10.1016\/j.ctrv.2025.103069_b0010","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3747\/co.27.5769","article-title":"A population-based analysis of breast cancer incidence and survival by subtype in Ontario women","volume":"27","author":"Seung","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2025.103069_b0015","unstructured":"NationalCancerInstitute. Cancer Stat Facts: Female Breast Cancer Subtypes. Surveillance, Epidemiology, and End Results Program. . [cited 2025 5\/2\/2025]; Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html."},{"issue":"20","key":"10.1016\/j.ctrv.2025.103069_b0020","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103069_b0025","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.ctrv.2025.103069_b0030","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103069_b0035","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","author":"Hortobagyi","year":"2024","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.ctrv.2025.103069_b0040","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-positive, High-Risk, Early Breast Cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2025.103069_b0045","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.3390\/cancers16162869","article-title":"Profiling the Cardiovascular Toxicities of CDK4\/6 Inhibitors: a Real-World Pharmacovigilance Study","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers"},{"issue":"38","key":"10.1016\/j.ctrv.2025.103069_b0050","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103069_b0055","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse Cardiovascular events Associated with Cyclin-Dependent Kinase 4\/6 Inhibitors in patients with Metastatic Breast Cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"10.1016\/j.ctrv.2025.103069_b0060","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes","volume":"67","author":"Schwartz","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103069_b0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaccao.2021.01.002","article-title":"How to Diagnose and Manage QT Prolongation in Cancer patients","volume":"3","author":"Kim","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103069_b0070","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae078","article-title":"QTc prolongation across CDK4\/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Murad","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103069_b0075","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1038\/s41598-024-53151-8","article-title":"Comparative overall survival of CDK4\/6 inhibitors in combination with endocrine therapy in advanced breast cancer","volume":"14","author":"Kappel","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2025.103069_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1269922","article-title":"The adverse events of CDK4\/6 inhibitors for HR+\/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials","volume":"15","author":"Pu","year":"2024","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103069_b0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5455\/medarh.2022.76.333-342","article-title":"The Combination of CDK 4\/6 Inhibitors plus Endocrine Treatment versus Endocrine Treatment Alone in Hormone-receptor (HR)-positive breast Cancer: a Systematic Review and Meta-analysis","volume":"76","author":"Hermansyah","year":"2022","journal-title":"Med Arch"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103069_b0090","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103069_b0095","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103069_b0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.breast.2016.06.008","article-title":"Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study","volume":"28","author":"Curigliano","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2025.103069_b0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejca.2021.11.010","article-title":"Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive\/HER2-advanced breast cancer: GEICAM\/2014-12 (FLIPPER)","volume":"161","author":"Albanell","year":"2022","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103069_b0180","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","article-title":"Randomized phase II Trial of Endocrine Therapy with or without Ribociclib after Progression on Cyclin-Dependent Kinase 4\/6 Inhibition in Hormone Receptor-positive, Human Epidermal Growth factor Receptor 2-negative Metastatic Breast Cancer: MAINTAIN Trial","volume":"41","author":"Kalinsky","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103069_b0105","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103069_b0165","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103069_b0215","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-positive, Human Epidermal Growth factor Receptor 2-negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103069_b0115","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal patients with HR+\/HER2- Advanced Breast Cancer in MONALEESA-7: a phase III Randomized Clinical Trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103069_b0220","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2025.103069_b0125","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+\/HER2- Advanced Breast Cancer who had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103069_b0110","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103069_b0200","doi-asserted-by":"crossref","unstructured":"Johnston, S., et al., MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer, 2019. 5(1): p. 5 DOI: 10.1038\/s41523-018-0097-z.","DOI":"10.1038\/s41523-018-0097-z"},{"key":"10.1016\/j.ctrv.2025.103069_b0195","article-title":"Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+\/HER2- advanced breast cancer: final results of the randomized phase III MONARCH plus trial","author":"Hu","year":"2024","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103069_b0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103069_b0210","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103069_b0140","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant Palbociclib for Early Breast Cancer: the PALLAS Trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103069_b0315","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.18.01624","article-title":"Randomized phase II Study evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor\u2013Positive Early Breast Cancer: PALLET Trial","volume":"37","author":"Johnston","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103069_b0320","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13058-016-0721-5","article-title":"Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103069_b0170","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103069_b0175","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103069_b0160","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103069_b0325","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in Combination with Fulvestrant in Women with Hormone Receptor-Positive\/HER2-negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis from a Multicenter, Randomized, Placebo-Controlled, phase III Study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2025.103069_b0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.08.012","article-title":"Palbociclib plus letrozole versus placebo plus letrozole in asian postmenopausal women with oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4","volume":"175","author":"Xu","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103069_b0190","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41523-024-00684-w","article-title":"A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive\/HER2-negative advanced breast cancer","volume":"10","author":"Noguchi","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"14","key":"10.1016\/j.ctrv.2025.103069_b0145","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-negative Early Breast Cancer\u2014The Penelope-B Trial","volume":"39","author":"Loibl","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103069_b0100","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib Plus Fulvestrant in Advanced Breast Cancer after Progression on CDK4\/6 Inhibition: results from the phase III postMONARCH Trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103069_b0205","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.breast.2020.08.011","volume":"54","author":"Schneeweiss","year":"2020","journal-title":"Breast"},{"issue":"15","key":"10.1016\/j.ctrv.2025.103069_b0155","doi-asserted-by":"crossref","first-page":"e7408","DOI":"10.1002\/cam4.7408","article-title":"Initial ribociclib plus endocrine therapy for HR+\/HER2- advanced breast cancer in pre- and postmenopausal chinese women: Primary results from a phase 2 randomized study","volume":"13","author":"Shao","year":"2024","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103069_b0185","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1007\/s00432-023-04588-3","article-title":"Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial","volume":"149","author":"Alsaleh","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103069_b0225","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14740338.2024.2307375","article-title":"A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4\/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system","volume":"23","author":"Yan","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103069_b0230","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-023-01338-z","article-title":"Use of Pharmacokinetic and Pharmacodynamic Data to develop the CDK4\/6 Inhibitor Ribociclib for patients with Advanced Breast Cancer","volume":"63","author":"Ji","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ctrv.2025.103069_b0235","unstructured":"Novartis. Kisqali Product Monograph. 2020 [cited 2025 18 March 2025]; Available from: https:\/\/www.novartis.com\/ca-en\/sites\/novartis_ca\/files\/kisqali_scrip_e.pdf."},{"issue":"2","key":"10.1016\/j.ctrv.2025.103069_b0240","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-020-05783-3","volume":"183","author":"Thein","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103069_b0245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaoncol.2018.5529","article-title":"Cyclin-Dependent Kinase Inhibitor-Associated Thromboembolism","volume":"5","author":"Olson","year":"2019","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2025.103069_b0250","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103069_b0255","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"41","key":"10.1016\/j.ctrv.2025.103069_b0260","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103069_b0265","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","article-title":"Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients","volume":"165","author":"Hu","year":"2013","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103069_b0270","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.mayocp.2023.04.013","article-title":"Clinical Trials Overview: from Explanatory to Pragmatic Clinical Trials","volume":"98","author":"Le-Rademacher","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103069_b0275","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/bcpt.13536","article-title":"Are older adults insufficiently included in clinical trials?\u2014An umbrella review","volume":"128","author":"Florisson","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103069_b0280","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12916-019-1427-1","article-title":"Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis","volume":"17","author":"Hanlon","year":"2019","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103069_b0285","doi-asserted-by":"crossref","first-page":"e2350963","DOI":"10.1001\/jamanetworkopen.2023.50963","article-title":"Cumulative Update of a Systematic Overview evaluating Interventions addressing Polypharmacy","volume":"7","author":"Keller","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103069_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0632","article-title":"Risk Assessment prior to Cardiotoxic Anticancer Therapies in 7 steps","volume":"86","author":"Tong","year":"2025","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.ctrv.2025.103069_b0295","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251326710","article-title":"Clinician's guide: expert insights on the use of CDK4\/6 inhibitors in patients with early breast cancer","volume":"17","author":"Hussain","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103069_b0300","article-title":"Assessing Adherence to Cardiac monitoring guidelines in Trastuzumab-Treated Breast Cancer patients: Insights from a Tertiary Hospital","volume":"15","author":"Alhuthali","year":"2023","journal-title":"Cureus"},{"issue":"Supplement_1","key":"10.1016\/j.ctrv.2025.103069_b0305","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.3188","article-title":"Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab","volume":"45","author":"Guerra","year":"2024","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103069_b0310","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jcmg.2024.01.009","article-title":"Cardiovascular magnetic Resonance Reference Ranges from the healthy Hearts Consortium","volume":"17","author":"Raisi-Estabragh","year":"2024","journal-title":"J Am Coll Cardiol Img"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:40:55Z","timestamp":1783712455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":65,"alternative-id":["S0305737225001914"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103069","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4\/6 inhibitors in hormone receptor-positive HER2-negative breast cancer \u2013 A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103069"}}